Advancing RSV Research Expanding Therapeutic Options with Recombinant Antibodies and Antigens

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=73lXViIp2aM

Presented By: Mohammad S. Safiarian, PhD • Speaker Biography: Dr. Mohammad Safiarian is the Associate Product Manager at Sino Biological, where he is responsible for product development and marketing of protein products. He earned his Ph.D. in Biochemistry from Georgia State University and completed post-doctoral trainings at the Georgia Institute of Technology and Baylor College of Medicine. Dr. Safiarian's expertise lies in protein science, DNA biochemistry, and enzymology, and he has authored several peer- reviewed papers with over 100 citations. • Webinar: Advancing RSV Research: Expanding Therapeutic Options with Recombinant Antibodies and Antigens with Live Q A • Webinar Abstract: Human respiratory syncytial virus (RSV) remains a significant public health concern, particularly for vulnerable populations such as infants, young children, and immunocompromised individuals. In this webinar we focus on the crucial role of RSV antigens and antibodies in research, and the development of diagnostics, therapeutics, and vaccines against RSV. We will provide a comprehensive overview of RSV, highlighting its epidemiology, clinical manifestations, and associated complications. Through this talk, we aim to showcase the power of recombinant antigens and antibodies in enhancing RSV detection, characterization, and understanding of viral pathogenesis. • Earn PACE Credits: • 1. Make sure you’re a registered member of Labroots (https://www.labroots.com/ms/webinar/a...) • 2. Watch the webinar on YouTube or on the Labroots Website (https://www.labroots.com/ms/webinar/a...) • 3. Click Here to get your PACE credits (Expiration date – September 07, 2025): (https://www.labroots.com/credit/pace-...) • Labroots on Social: • Facebook: / labrootsinc • Twitter: / labroots • LinkedIn: / labroots • Instagram: / labrootsinc • Pinterest: / labroots • SnapChat: labroots_inc

#############################

New on site